’Reddit is built for this moment’ - Stock soars on crushed earnings
CAMBRIDGE, MA—Jacqualyn Fouse, a director at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold shares worth approximately $194,172, according to a Form 4 filing with the Securities and Exchange Commission. The transaction, which took place on April 10, 2025, involved the sale of 7,497 shares at a price of $25.90 each. This sale was part of a planned transaction to cover tax obligations related to the vesting of performance share units. The stock, which has declined 37% over the past six months, currently appears undervalued according to InvestingPro analysis.
Prior to this sale, on April 8, 2025, Fouse acquired 15,933 shares of common stock through the conversion of restricted stock units. These shares were acquired at no cost, as part of a vesting schedule initiated in April 2022. After the transactions, Fouse holds a total of 149,220 shares in the company. With the next earnings report due on May 1, 2025, investors can access comprehensive analysis and 8 additional key insights through InvestingPro's detailed research report.
Agios Pharmaceuticals, based in Cambridge, Massachusetts, is engaged in the development of pharmaceutical preparations. The company continues to focus on advancing its pipeline of innovative therapies. Despite challenging market conditions, Agios maintains a strong financial position with more cash than debt and a healthy current ratio of 11.9x, indicating robust short-term liquidity.
In other recent news, Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share of -$1.44 compared to the forecast of -$1.68. The company also exceeded revenue projections, reporting $10.7 million against an anticipated $9.32 million. Agios demonstrated strong performance, driven by a 51% year-over-year increase in net revenue from Pyrakind, their lead product. Additionally, the company ended the quarter with a solid cash position of $1.5 billion, which it plans to utilize for future growth and product development.
H.C. Wainwright recently initiated coverage on Agios Pharmaceuticals, assigning a Buy rating and setting a price target of $58.00. The firm expressed optimism about Agios's lead asset, mitapivat, which has already received FDA approval for the treatment of adult pyruvate kinase deficiency. Analysts from H.C. Wainwright anticipate potential label expansions for mitapivat into larger patient populations, such as thalassemia and sickle cell disease, by 2026. This expansion could significantly increase the therapy's reach and impact.
Agios is preparing for a potential commercial launch in thalassemia with a PDUFA date set for September 7, 2025, and aims for a later expansion into sickle cell disease in the second half of 2026. The company is also making progress in its product pipeline, with significant advancements in trials and regulatory filings. These developments are part of Agios's broader strategy to maximize its Pyrakind franchise and advance its pipeline programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.